Adjunctive Vortioxetine in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Real-World Pilot Study from Malaysia
Pharmacoepidemiology · 20.05.2026 · 5 (2) · 14
DOI: 10.3390/pharma5020014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology, online erschienen am 20.05.2026. Verfasst von Tharishini Ramachandran und 3 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A significant percentage of patients with major depressive disorder (MDD) fail to achieve remission with antidepressant monotherapy and frequently experience residual mood and cognitive symptoms that impair their functional recovery. Thus, an augmentation with vortioxetine, a multimodal antidepressant with reported cognitive benefits, might be a useful strategy for such patients.
Methods
We conducted a 12-week naturalistic, prospective observational study in a Malaysian university hospital; 40 adults with MDD and inadequate response to at least eight weeks of antidepressant therapy received either adjunctive vortioxetine or optimization of their existing antidepressant as part of treatment-as-usual care. Depressive symptoms were assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS), cognitive symptoms using the Perceived Deficits Questionnaire-5 (PDQ-D5), and global improvement using the Clinical Global Impressions—Improvement (CGI-I) scale.
Results
Both groups demonstrated significant improvements in MADRS and PDQ-D5 scores over 12 weeks (p < 0.001). Remission rates at Week 12 were high in both groups (93.8% adjunctive vortioxetine vs. 86.7% control). Both groups demonstrated significant improvements in depressive and cognitive symptoms over 12 weeks. Although between-group differences were not statistically significant, descriptive trends toward earlier symptomatic improvement were observed in the adjunctive vortioxetine group in several core depressive symptoms, including apparent sadness, suicidal ideation, and appetite disturbance. Greater clinician-rated global improvement was observed in the vortioxetine group at Week 12 (87.5% vs. 40.0%, p < 0.001).
Conclusions
In this outpatient clinical setting, adjunctive vortioxetine was associated with earlier improvement of core depressive symptoms and greater global clinical improvement compared with optimization of existing antidepressant therapy. Collectively, these findings suggest adjunctive vortioxetine as a clinically relevant option for patients with MDD who show an inadequate response to antidepressant monotherapy; however, findings are exploratory and not causal, and thus larger RCTs are needed for affirmation.
Zitieren
APA
Ramachandran, T., Ng, C. G., Wong, J. J. I., & Adlan, A. S. A. (2026). Adjunctive Vortioxetine in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Real-World Pilot Study from Malaysia. Pharmacoepidemiology, 5(2), 14. https://doi.org/10.3390/pharma5020014
Vancouver
Ramachandran T, Ng CG, Wong JJI, Adlan ASA. Adjunctive Vortioxetine in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Real-World Pilot Study from Malaysia. Pharmacoepidemiology. 2026;5(2):14. doi:10.3390/pharma5020014
BibTeX
@article{Ramachandran2026,
author = {Ramachandran, Tharishini and Ng, Chong Guan and Wong, Julian Joon Ip and Adlan, Aida Syarinaz Ahmad},
title = {Adjunctive Vortioxetine in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Real-World Pilot Study from Malaysia},
journal = {Pharmacoepidemiology},
year = {2026},
volume = {5},
number = {2},
pages = {14},
doi = {10.3390/pharma5020014}
}
EUVIMED